Dafne Capelusnik

Dafne Capelusnik

Auto-generated profile, based on publicly available information

Dafne Capelusnik

Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, the Netherlands; Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2025 in The Lancet
Verified
Journal Article
Closed access
VNVictoria Navarro-Compán
Victoria Navarro-Compán
Alexandre SeprianoAlexandre Sepriano
Alexandre Sepriano
DCDafne Capelusnik
Dafne Capelusnik
XBXenofon Baraliakos
Xenofon Baraliakos

15 June 2023 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
VNVictoria Navarro-Compán
Victoria Navarro-Compán
DBDiego Benavent
Diego Benavent
DCDafne Capelusnik
Dafne Capelusnik
DHDésirée van der Heijde
Désirée van der Heijde
RLRobert Bm Landewé
Robert Bm Landewé
SRSofia Ramiro
Sofia Ramiro
Objectives To develop a consensual definition for the term ‘early axial spondyloarthritis—axSpA’—and ‘early peripheral spondyloarthritis—pSpA’. Methods The ASAS (Assessment of SpondyloArthritis international Society-Spondyloarthritis EARly definition) steering committee convened an international working group (WG). Five consecutive steps were followed: (1) systematic literature review (SLR); (2) discussion of SLR results within the WG and ASAS community; (3) a three-round Delphi survey inviting all ASAS members to select the items that should be considered for the definition; (4) presentation of Delphi results to the WG and ASAS community and (5) ASAS voting and endorsement (2023 annual meeting). Results Following the SLR, consensus was to proceed with an expert-based definition for early axSpA (81% in favour) but not for pSpA (54% against). Importantly, early axSpA should be based on symptom duration taking solely axial symptoms into account. 151–164 ASAS members participated in the Delphi surveys. Consensus was achieved for considering the following items within early axSpA definition: duration of symptoms ≤2 years; axial symptoms defined as cervical/thoracic/back/buttock pain or morning stiffness; regardless of the presence/absence of radiographic damage. The WG agreed that in patients with a diagnosis of axSpA ‘early axSpA’ should be defined as a duration of ≤2 years of axial symptoms. Axial symptoms should include spinal/buttock pain or morning stiffness and should be considered by a rheumatologist as related to axSpA. The ASAS community endorsed this proposal (88% in favour). Conclusions Early axSpA has newly been defined, based on expert consensus. This ASAS definition should be adopted in research studies addressing early axSpA.

13 September 2022 in Rheumatology
Verified
Journal Article
Closed access
PDF file
DCDafne Capelusnik
Dafne Capelusnik
DBDiego Benavent
Diego Benavent
DHDésirée van der Heijde
Désirée van der Heijde
RLRobert Landewé
Robert Landewé
DPDenis Poddubnyy
Denis Poddubnyy
SRSofia Ramiro
Sofia Ramiro
To summarize evidence on the relationship between early treatment (definition based on symptom/disease duration or radiographic damage) and treatment clinical response in patients with SpA. A systematic literature review was conducted in studies on SpA patients treated with NSAIDs or biological/targeted synthetic DMARDs addressing the impact of symptom/disease duration or presence of radiographic damage on treatment response assessed by any disease activity outcome. For categorical outcomes, relative risk, relative risk ratio and number needed to treat were calculated, and for continuous outcomes, differences in differences, to compare groups stratified based on symptom/disease duration or the presence of radiographic damage. From the 8769 articles retrieved, 25 were included and 2 added by hand-search, all in axial SpA (axSpA), most of them with low risk of bias. Twenty-one studies compared groups based on symptom duration (n = 6) or disease duration (n = 15) and seven studies based on absence/presence of radiographic damage (two studies used two comparisons). When early axSpA was defined by symptom duration (<5 years) in randomized controlled trials, early treatment was associated with better outcomes in patients with non-radiographic axSpA [n = 2, ASAS40 relative risk ratio 5.24 (95% CI 1.12, 24.41) and 1.52 (0.60, 3.87)] but not in radiographic axSpA (n = 1) [ASAS20 0.96 (0.53–1.73)]. When early axSpA was defined based on disease duration or radiographic damage, no differences were found between groups. Evidence towards better outcomes in early axSpA is very limited and restricted to non-radiographic axSpA and <5 years symptom duration. When early axSpA is defined based on disease duration or radiographic damage, no differences in response to treatment are found.

12 September 2022 in RMD Open
Verified
Journal Article
Open access
PDF file
DBDiego Benavent
Diego Benavent
DCDafne Capelusnik
Dafne Capelusnik
SRSofia Ramiro
Sofia Ramiro
AMAnna Molto
Anna Molto
Clementina López-MedinaClementina López-Medina
Clementina López-Medina
VNVictoria Navarro-Compán
Victoria Navarro-Compán
Objectives To investigate the influence of gender on disease outcomes in patients with spondyloarthritis (SpA), including across SpA subtypes. Methods Data from 4185 patients of 23 countries with a diagnosis of axial SpA (axSpA), peripheral SpA (pSpA) or psoriatic arthritis (PsA) from the Assessment of SpondyloArthritis International Society (ASAS)-perSpA study were analysed. Associations between gender and disease activity (Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath Ankylosing Spondylitis Disease Activity Score (BASDAI), C-reactive protein (CRP)), function (Bath Ankylosing Spondylitis Functional Index (BASFI)) and overall health (ASAS Health Index (ASAS HI), European Quality of Life Five Dimension (EQ-5D)) outcomes were investigated. Multilevel multivariable linear mixed models adjusted for relevant confounders (and stratified by disease subtype in case of a relevant interaction) were used. Results In total, 65%, 10% and 25% of patients had axSpA, pSpA and PsA, respectively. axSpA was more frequent in males (68%), whereas pSpA and PsA were more frequent in females (53% and 52%, respectively). A significant interaction between gender and disease subtype was found for ASDAS, BASDAI and BASFI. While being female independently contributed to higher BASDAI across the three disease subtypes (with varying magnitude), female gender was only associated with higher ASDAS in pSpA (β (95% CI): 0.36 (0.15 to 0.58)) and PsA (0.25 (0.12 to 0.38)) but not in axSpA (0.016 (−0.07 to 0.11)). No associations were observed between gender and CRP levels. Female gender was associated with higher ASAS HI and EQ-5D, without differences across disease subtype. Conclusion Female gender is associated with less favourable outcome measures across the SpA spectrum. However, while female gender influences BASDAI across the three subtypes, ASDAS is associated with gender only in pSpA and PsA but not in axSpA. Therefore, ASDAS is an appropriate instrument both for females and males with axSpA.


15 July 2025 in RMD Open
Verified
Journal Article
Open access
PDF file
Clementina López-MedinaClementina López-Medina
Clementina López-Medina
DCDafne Capelusnik
Dafne Capelusnik
CWCasper Webers
Casper Webers
FBFilip Van Den Bosch
Filip Van Den Bosch
ABAnnelies Boonen
Annelies Boonen
SRSofia Ramiro
Sofia Ramiro
Background: Unravelling the performance of disease activity measures in peripheral spondyloarthritis (pSpA) is crucial for the development of clinical studies. We aimed to evaluate the construct validity and discriminatory capacity of various instruments assessing disease activity and response criteria in patients with pSpA. Methods: Post-hoc analysis of the CRESPA randomised controlled trial including patients with early active pSpA. Patients were randomised to golimumab (GOL) or placebo (PBO). Data of the placebo-controlled part until week 12 were used. Construct validity (known group discrimination assessed with standardised mean difference, SMD) in the 12-week data, longitudinal construct validity (ie, standardised response mean and effect size) and trial discrimination (SMD) of several disease activity instruments were assessed. As part of trial discrimination, a χ2 test was performed for binary outcomes. Results: A total of 60 patients (40 GOL, 20 PBO) were included. Construct validity was better for composite outcomes (ie, Disease Activity in Psoriatic Arthritis (DAPSA), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Axial Spondyloarthritis Disease Activity Score (ASDAS)—higher SMD between active and inactive patients). Longitudinal construct validity was consistently good for composite outcomes (eg, ASDAS, DAPSA) and global assessments (Patient Global Assessment (PGA), Physician Global Assessment (PhGA)). Clinical trial discrimination was good for composites (BASDAI, ASDAS, DAPSA), global assessments (PGA, PhGA) and joint counts (swollen joint count (SJC66) and tender joint count (TJC68)). Among binary outcomes, trial discrimination was strongest for clinical remission (ie, absence of arthritis, enthesitis and dactylitis), BASDAI50, DAPSA-Low Disease Activity (LDA) and ASDAS-LDA. Conclusion: While both composite and global outcome measurement instruments performed well in pSpA, composite scores like DAPSA, ASDAS and BASDAI showed better construct validity. The clinical remission definition was the most discriminatory response criterion.